CROSSJECTCROSSJECTCROSSJECT

CROSSJECT

No trades
See on Supercharts

ALCJ fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Crossject SA manufactures and markets needle free injection system. It develops and produces generic drugs such as methotrexate, epinephrin, and sumatriptan. The company distributes its products under the Zeneo brand. Crossject was founded by Patrick Alexandre and Xavière Castano on August 8, 2001 and is headquartered in Dijon, France.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

ALCJ does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company